Exelixis
EXEL
#1786
Rank
A$15.11 B
Marketcap
$52.94
Share price
-0.09%
Change (1 day)
59.50%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2025A$1.25 M-89.58%
2024A$12.08 M86.29%
2023A$6.48 M-41.81%
2022A$11.14 M-31.9%
2021A$16.36 M-20.71%
2020A$20.64 M303.63%
2019A$5.11 M-70.5%
2018A$17.33 M8.82%
2017A$15.92 M-17.35%
2016A$19.27 M-75.68%
2015A$79.23 M19.37%
2014A$66.37 M258.49%
2013A$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
A$95.08 MA$0.14 B๐Ÿ‡ฌ๐Ÿ‡ง UK
A$4.02 MA$72.89 M๐Ÿ‡ซ๐Ÿ‡ท France
A$76.76 MA$0.12 B๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.17 BA$0.47 B๐Ÿ‡บ๐Ÿ‡ธ USA
A$36.48 MA$0.25 B๐Ÿ‡บ๐Ÿ‡ธ USA
A$21.76 MA$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
A$28.68 MA$0.33 B๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.22 MA$0.91 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AA$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA